BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Avid Bioservices, Inc. Secures Biomanufacturing Contract With Affitech AS


9/30/2010 9:03:46 AM

TUSTIN, CA--(Marketwire - September 30, 2010) - Avid Bioservices, Inc., a leading provider of integrated biomanufacturing services and a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced it has secured a biomanufacturing contract to supply clinical material over the coming year to Affitech A/S (COPN: AFFI), the antibody medicines company. The initial contract for committed services provides for several large-scale cGMP manufacturing runs as well as other cGMP-related services.

"Given our long-term relationship, Avid is an ideal partner for providing biomanufacturing services for our fully human antibody AT001/r84, as they have direct experience with Peregrine's anti-VEGF technology platform as well as this novel antibody we discovered from this technology," said Martin Welschof, Managing Director of Affitech. "Over the coming year, we look forward to having Avid's support as we expedite our clinical development plans for AT001/r84 for select growing pharmaceutical markets."

About AT001/r84
AT001/r84 is a fully human, selective therapeutic antibody to vascular endothelial growth factor (VEGF) and has demonstrated encouraging effects on immune cells in preclinical models. Using Peregrine's anti-VEGF antibody technology platform, Affitech discovered AT001/r84, a fully human, selective blocker of VEGF binding to VEGF receptor 2 (VEGFR2).

About Avid Bioservices
Avid Bioservices provides a comprehensive range of high quality cGMP manufacturing services for the biotechnology and biopharmaceutical industries to support manufacturing of cGMP commercial and clinical products. With over 10 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cell banking, stability testing, clinical and commercial product manufacturing and purification, bulk packaging, final product filling and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.


Contact:
Amy Figueroa
Peregrine Pharmaceuticals
(800) 987-8256
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES